SET Announcements

Notification of the Resolutions of the Extraordinary General Meeting of Shareholders No. 1/2022
Management Discussion and Analysis Quarter 2 Ending 30 Jun 2022
Financial Performance Quarter 2 (F45) (Reviewed)
Financial Statement Quarter 2/2022 (Reviewed)
Disclosure of invitation to the Extraordinary General Meeting of Shareholders No. 1/2022 on the Company's website
Report on use of proceed from IPO ended 30 June 2022
Notification of the Resolutions of the Board of Director' s Meeting No. 4/2022, the Schedule of Meeting and the Agendas of the Extraordinary Meeting of Shareholder No. 1/2022 ("EGM") (Revised No. 1)
Establishment of Innovation center and small-scale production facility of dietary supplements and cosmetics
Establishment of a new subsidiary
Notification of the Resolutions of the Board of Director' s Meeting No. 4/2022, the Schedule of Meeting and the Agendas of the Extraordinary Meeting of Shareholder No. 1/2022 ("EGM")
Management Discussion and Analysis Quarter 1 Ending 31 Mar 2022
Financial Performance Quarter 1 (F45) (Reviewed)
Financial Statement Quarter 1/2022 (Reviewed)
Disclosure of minute of meeting of the Annual General Meeting of Shareholders year 2022 on the Company's website
Shareholders meeting's resolution
Disclosure of invitation to the Annual General Meeting of Shareholders year 2022 on the Company's website
Notification of Resolution of the Board of Directors Meeting No.2/2022 and the Annual General Meeting of Shareholders Schedule and Agenda for the Year 2022 (AGM) (Revised meeting channel)
Notification of Resolution of the Board of Directors Meeting No.2/2022 and the Annual General Meeting of Shareholders Schedule and Agenda for the Year 2022 (AGM) (Revised)
Notification of Resolution of the Board of Directors Meeting No.2/2022 and the Annual General Meeting of Shareholders Schedule and Agenda for the Year 2022 (AGM)
Financial Performance Yearly (F45) (Audited)
Management Discussion and Analysis Yearly Ending 31 Dec 2021
Financial Statement Yearly 2021 (Audited)
Notification of Resolution of the Board of Directors Meeting No.2/2022 and the Annual General Meeting of Shareholders Schedule and Agenda for the Year 2022 (AGM)
Report on receive of Narcotics Substance Type 5 License (Hemp only)
Report on use of proceed from IPO ended 31 December 2021